Brawn Biotech Limited has announced its unaudited standalone financial results for the quarter and nine months ended December 31, 2025, under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance Overview

The pharmaceutical company reported its Q3 FY26 financial performance with the following key metrics:

Expense Structure

The company's expense breakdown for the quarter included employee benefit expenses, depreciation and amortization expenses, finance costs, and other operational expenses. The total expenses for Q3 FY26 were managed within the operational framework of the pharmaceutical business.

Earnings Per Share

The company reported earnings per share metrics for the quarter:

Corporate Information

Brawn Biotech Limited operates primarily in the pharmaceutical business sector. The company's registered office is located at C-64, Lajpat Nagar-1, New Delhi 110024, with manufacturing works at Plot No.44, Pace City-1, Sector 37, Near Hero Honda Chowk, Gurugram, Haryana.

Regulatory Compliance

The financial results were prepared in compliance with Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013. The results were reviewed by statutory auditors Rajiv Udai & Associates, Chartered Accountants, and approved by the Board of Directors at a meeting held on February 14, 2026.

The company's CFO has certified the financial results under Regulation 33(2)(a) of SEBI (LODR) Regulations, 2015, confirming that the statements present a true and fair view of the entity's affairs and comply with existing accounting standards and applicable regulations.

Brawn Biotech Limited has announced a key leadership appointment, naming Ms. Rati Garg as the company's new Chief Financial Officer and Key Managerial Personnel. The appointment, which takes effect from February 1, 2026, was approved during the Board of Directors meeting held on January 30, 2026.

Board Meeting Details

The board meeting was conducted on January 30, 2026, commencing at 10:00 AM and concluding at 10:30 AM (IST). The appointment decision was made based on the recommendation of the company's Nomination and Remuneration Committee, demonstrating the structured governance process followed by the organization.

New CFO Profile and Qualifications

Ms. Rati Garg brings substantial expertise to her new role, with over 15 years of extensive experience across multiple financial domains. Her professional background encompasses financial management, cost control, budgeting, and regulatory compliance. She possesses strong expertise in financial planning and analysis (FP&A), cost optimization, and internal controls.

Areas of Expertise

The new CFO's comprehensive skill set includes:

• Financial planning and analysis (FP&A)
• Cost optimization and control
• Internal controls implementation
• Statutory and cost audits
• Taxation matters
• Corporate finance
• Budgeting and regulatory compliance

Regulatory Compliance

The appointment was announced in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company also referenced SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, and Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, ensuring full regulatory adherence.

The formal communication was submitted to BSE Limited, where Brawn Biotech Limited is listed under scrip code 530207. Company Secretary and Compliance Officer Priyanka Sharma signed the official notification, maintaining the company's commitment to transparent corporate governance and timely disclosure of material information to stakeholders.